



UMC Utrecht
Julius Center

Developing and validating prediction models using large clustered datasets and meta-analysis

Thomas Debray, PhD

Assistant Professor

Julius Center for Health Sciences and Primary Care



Prediction

- Risk prediction = foreseeing / foretelling
... (probability) of something that is yet unknown
- Turn available information (predictors) into a statement about the probability:
 - ... of having a particular disease -> **diagnosis**
 - ... of developing a particular event -> **prognosis**
- Use of prognostic information:
 - to inform patients and their families
 - to guide treatment and other clinical decisions
 - to create risk groups
 - ...




How do we predict?

- Combine information from multiple predictors
 - Subject characteristics (e.g. age, gender)
 - History and physical examination results (e.g. blood pressure)
 - Imaging results
 - (Bio)markers (e.g. coronary plaque)
- Develop a multivariable statistical model
 - Need for patient data from large cohort studies
 - Many strategies available (Regression, decision trees, neural networks, ...)



What is a good model?



Common pitfalls

Most models are not as good as we think

- Limited sample size
- Flaws in design & analysis
- Incomplete/selective reporting
- Lack of external validation



Most models are not as good as we think

Clinical prediction models are not being validated

[Peter Tugwell](#), [J. André Knottnerus](#) (Editors) 



External validation of new risk prediction models is infrequent and reveals worse prognostic discrimination

George C.M. Siontis^{a,1}, Ioanna Tzoulaki^{a,b}, Peter J. Castaldi^c, John P.A. Ioannidis^{d,e,f,*}



External validation of multivariable prediction models: a systematic review of methodological conduct and reporting


Gary S Collins^{1*}, Joris A de Groot², Susan Dutton¹, Omar Omar¹, Milensu Shanyinde¹, Abdelouahid Tajar¹, Meryn Voysey¹, Rose Wharton¹, Ly-Mee Yu¹, Karel G Moons² and Douglas G Altman¹

Assessment of Claims of Improved Prediction Beyond the Framingham Risk Score


Ioanna Tzoulaki, PhD; George Liberopoulos, MD; John P. A. Ioannidis, MD



Most models are not as good as we think



Collins et al (BMC Med Res Methodol 2014)



Siontis et al (J Clin Epidemiol 2014)

Most models are not as good as we think

Lack of generalizability across settings & (sub)populations

- Poor reproducibility
 - Overfitting to the data at hand
- Poor transportability
 - Differences in patient spectrum
 - Differences in measurement methods
 - Changes in standards of care and treatment strategies
 - ...



Use of large, clustered, datasets

Research partially funded by my VENI grant (91617050)
"Better predictions using big data sets"



Use of large clustered data sets

thebmj

Research ▾

Education ▾

News & Views ▾

Campaigns ▾

Archive

Research Methods & Reporting

External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges

BMJ 2016 ; 353 doi: <https://doi.org/10.1136/bmj.i3140> (Published 22 June 2016)

Cite this as: *BMJ* 2016;353:i3140



GUIDELINES AND GUIDANCE

Individual Participant Data (IPD) Meta-analyses of Diagnostic and Prognostic Modeling Studies: Guidance on Their Use

Thomas P. A. Debray^{1,2*}, Richard D. Riley³, Maroeska M. Rovers⁴, Johannes B. Reitsma^{1,2}, Karel G. M. Moons^{1,2}, Cochrane IPD Meta-analysis Methods group¹

Use of large clustered data sets

Potential advantages

- Development of better prediction models
 - Reduced risk of overfitting
 - Ability to address wider spectrum of patients
 - Ability to investigate more complex associations
- More extensive testing of model performance
 - Ability to externally validate across multiple settings
 - Ability to investigate sources of heterogeneity
 - Ability to improve or tailor the model



Model development

- Need to identify whether aggregation of multiple data sources is justifiable
 - Differences in included populations
 - Differences in measurement methods
 - Differences in treatment standards
- Need to account for heterogeneity across settings
 - Differences in outcome prevalence (or incidence)
 - Differences in predictor effects
 - Failing to account for clustering may cause prediction models to yield poor performance across different (sub)populations!

Implement a framework that uses internal-external cross-validation



Internal-external cross-validation (IECV)



PDF



Info

Statistics
in Medicine



[Explore this journal >](#)

Research Article

A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis

Thomas P.A. Debray [✉](#), Karel G.M. Moons, Ikhlaaq Ahmed, Hendrik Koffijberg, Richard David Riley

First published: 11 January 2013 [Full publication history](#)



[View issue TOC](#)
Volume 32, Issue 18
15 August 2013
Pages 3158–3180



ELSEVIER

Journal of Clinical Epidemiology

Volume 69, January 2016, Pages 245-247




Commentary

Prediction models need appropriate internal, internal–external, and external validation


Ewout W. Steyerberg [✉](#) ^a, Frank E. Harrell Jr. ^b

Internal-external cross-validation (IECV)



Internal-external cross-validation (IECV)

The IECV approach allows for many external validations



Assessing model performance

Synthesis of performance estimates

- A 'good' prediction model should have
 - satisfactory performance on average
 - little or no between-study heterogeneity in performance
- Meta-analysis may help ...
 - To estimate likely performance in new studies
 - To identify sources of heterogeneity
 - To evaluate different modeling strategies
 - To distinguish between reproducibility and transportability
 - To identify "boundaries" of model generalizability



Assessing model performance



A new framework to enhance the interpretation of external validation studies of clinical prediction models

Thomas P.A. Debray^{a,*}, Yvonne Vergouwe^b, Hendrik Koffijberg^a, Daan Nieboer^b,
Ewout W. Steyerberg^{b,1}, Karel G.M. Moons^{a,1}



Multivariate meta-analysis of individual participant data helped externally validate the performance and implementation of a prediction model

Kym I.E. Snell^a, Harry Hua^b, Thomas P.A. Debray^{c,d}, Joie Ensor^e,
Maxime P. Look^f, Karel G.M. Moons^{c,d}, Richard D. Riley^{e,*}



**Meta-analysis of prediction model performance across multiple studies:
Which scale helps ensure between-study normality for the C-statistic and
calibration measures?**

[Kym IE Snell, Joie Ensor, Thomas PA Debray, ...](#)

[Show all authors](#)




**A guide to systematic review and meta-analysis of prediction
model performance**

Thomas P A Debray,^{1,2} Johanna A A G Damen,^{1,2} Kym I E Snell,³ Joie Ensor,³ Lotty Hoofst,^{1,2}
Johannes B Reitsma,^{1,2} Richard D Riley,³ Karel G M Moons^{1,2}


Assessing model performance

Investigation of heterogeneity across settings












































































































Summary C statistic = 0.83 (95% CI 0.826 to 0.833)
95% prediction interval for true C statistic in a new practice = 0.76 to 0.88

Concordance statistic for QRISK2, for each of the 364 included general practices (N ≈ 2,000,000)



Calibration of QRISK2 and the Framingham risk score in women aged 35 to 74 years

Study 1	Corr: 0.986	Corr: 0.941	Corr: 0.919	Corr: 0.958	Corr: 0.842	Corr: 0.922	Corr: 0.941	Corr: 0.885	Corr: 0.944	Corr: 0.969	Corr: 0.96	Corr: 0.937	Corr: 0.959	Corr: 0.876
	Study 2	Corr: 0.93	Corr: 0.928	Corr: 0.861	Corr: 0.85	Corr: 0.928	Corr: 0.95	Corr: 0.856	Corr: 0.97	Corr: 0.97	Corr: 0.977	Corr: 0.933	Corr: 0.952	Corr: 0.92
		Study 3	Corr: 0.916	Corr: 0.94	Corr: 0.895	Corr: 0.972	Corr: 0.933	Corr: 0.926	Corr: 0.951	Corr: 0.945	Corr: 0.962	Corr: 0.965	Corr: 0.948	Corr: 0.926
			Study 4	Corr: 0.918	Corr: 0.907	Corr: 0.935	Corr: 0.888	Corr: 0.815	Corr: 0.958	Corr: 0.939	Corr: 0.952	Corr: 0.936	Corr: 0.89	Corr: 0.907
				Study 5	Corr: 0.869	Corr: 0.929	Corr: 0.924	Corr: 0.827	Corr: 0.97	Corr: 0.954	Corr: 0.99	Corr: 0.951	Corr: 0.956	Corr: 0.951
					Study 6	Corr: 0.876	Corr: 0.823	Corr: 0.835	Corr: 0.905	Corr: 0.937	Corr: 0.883	Corr: 0.965	Corr: 0.888	Corr: 0.9
						Study 7	Corr: 0.965	Corr: 0.879	Corr: 0.973	Corr: 0.919	Corr: 0.965	Corr: 0.931	Corr: 0.902	Corr: 0.936
							Study 8	Corr: 0.905	Corr: 0.958	Corr: 0.918	Corr: 0.942	Corr: 0.894	Corr: 0.917	Corr: 0.912
								Study 9	Corr: 0.861	Corr: 0.898	Corr: 0.844	Corr: 0.89	Corr: 0.923	Corr: 0.84
									Study 10	Corr: 0.96	Corr: 0.967	Corr: 0.95	Corr: 0.927	Corr: 0.973
										Study 11	Corr: 0.955	Corr: 0.976	Corr: 0.96	Corr: 0.919
											Study 12	Corr: 0.957	Corr: 0.946	Corr: 0.958
												Study 13	Corr: 0.967	Corr: 0.931
													Study 14	Corr: 0.907
														Study 15

More guidance underway!

- Future book chapters
 - Collins GS, Moons KGM, Debray TPA, Altman DG, Riley RD. **Systematic reviews of prediction models.** Systematic Reviews in Health Care: Meta-Analysis in Context (Wiley)
 - Riley TD, Debray TPA, Moons KGM. **Individual Participant Data Meta-analysis of Prognosis Studies.** Evidence synthesis using individual participant data: concepts, methods, and guidance for clinical research (CRC Press)
 - Steyerberg EW, Nieboer D, Debray TPA, van Houwelingen H. **Meta-analysis of prediction models.** Handbook of Meta-analysis (CRC Press)
- Courses
 - MSc Epidemiology
 - Elevate
 - Cochrane